US stock market unusual movement | Cytokinetics' drug AFICAITA approved for listing, Cytokinetics (CYTK.US) soars more than 10%

Wisdom Financial APP learned that on Monday, Cytokinetics (CYTK.US) surged more than 10%, hitting a new high for the year at $69.34 per share. In terms of news, recently, the National Medical Products Administration approved Cytokinetics, Incorporated's application for a priority review and approval procedure for the listing of the innovative drug Afketayi (trade name: Xingshuping), which is used to treat obstructive hypertrophic cardiomyopathy (HCM) in adult patients with New York Heart Association (NYHA) functional class II-III, to improve exercise capacity and symptoms.